



True precision medicine through single-cell science

- Best-in-class single-cell biomarker discovery algorithm
- Validated, patent-pending biomarkers for two indications
- First commercial deals signed and a global network of partners



Key achievement


We have signed three high-profile strategic partnerships, securing long-term revenue and validating our business model

- Co-development of an assay for prediction of treatment response in Non-Small Cell Lung Cancer with Genius

[Press release.](#)

- Identification and diagnosis of rare disease patients with Volv Global

[Press release](#)



Outlook for Q2-2021

- Generating new proprietary data to discover new biomarker signatures.
- Ongoing commercial outreach, aiming to secure new partnerships.

- Co-development of two clinical diagnostic assays for immunology indications with Apis Assay Technologies

Scailyte will perform the biomarker discovery, and Apis will develop and commercialize diagnostic assays based on the discovered biomarkers. The partnership model includes sharing of costs in the R&D phase and profits-sharing for the entire product lifetime.

We are kicking-off our Series A financing round!

We aim to raise 10 mln CHF to support our commercial projects, R&D and to expand the team.

[Get in touch with us!](#)





True precision medicine through single-cell science

- Best-in-class single-cell biomarker discovery algorithm
- Validated, patent-pending biomarkers for two indications
- First commercial deals signed and a global network of partners



Prof. Woong-Yang Park

Founder and CEO of Geninus



“Geninus aims to implement single-cell genome analysis techniques to facilitate personalized patient care. Scailyte’s machine learning model will add value to the single-cell gene expression profile of patients. Through collaboration with Scailyte, we hope to provide prognostic methods for immunotherapy response in precision medicine clinics.”

Profile

Prof. Park is an accomplished geneticist, with over 100 highly cited publications and several patents on his account. He founded Geninus in spring 2018 to commercialise the scientific advancements of the Samsung Genome Institute. He was initially approached by Scailyte as a clinical key opinion leader and soon identified the potential for a strategic partnership with the commercial aim.

“Precision medicine is poised to become a standard in the future, however today it is facing a major obstacle: a data problem. The robust analytical engine of Scailyte makes it an enabler of precision medicine. We decided to support the company because we believe in the technology, as well as in the talented team behind it.”

Profile

Dominique Mégret is the Head of the venture unit of the largest telecom provider in Switzerland. Swisscom Ventures invests in digital technologies and teams who have the ambition to become global leaders in their respective verticals. Dominique serves on Scailyte’s board of directors since 2018, supporting the company with his entrepreneurial as well as venture capital experience.

Dominique Mégret

Scailyte Board of Directors
& Head Swisscom Ventures

